We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
-1.21%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.35B
AUM Growth
+$59.1M
Cap. Flow
+$135M
Cap. Flow %
9.97%
Top 10 Hldgs %
58.23%
Holding
42
New
1
Increased
8
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
BN icon
Brookfield
BN
+$110M
2
BAM icon
Brookfield Asset Management
BAM
+$21.2M
3
CABO icon
Cable One
CABO
+$16M
4
INSP icon
Inspire Medical Systems
INSP
+$6.94M
5
IOBT
IO Biotech
IOBT
+$4.34M

Top Sells

Rank Stock Value
1
VERV
Verve Therapeutics
VERV
+$9.38M
2
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
+$8.23M
3
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
+$6.55M
4
CBAY
Cymabay Therapeutics
CBAY
+$5.75M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$5.04M

Sector Composition

Rank Sector Weight
1 Healthcare 51.32%
2 Technology 24.11%
3 Financials 10.51%
4 Industrials 5.46%
5 Communication Services 5.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
26
Rocket Pharmaceuticals
RCKT
$394M
$20.5M 1.52%
1,001,000
+81,000
+9% +$1.47M
FDMT icon
27
4D Molecular Therapeutics
FDMT
$562M
$15.3M 1.13%
1,200,000
+200,000
+20% +$3.35M
SPRB
28
Spruce Biosciences
SPRB
$129M
$15.2M 1.12%
89,631
– –
INSP icon
29
Inspire Medical Systems
INSP
$1.74B
$11.9M 0.88%
60,000
+27,500
+85% +$6.94M
IOBT
30
DELISTED
IO Biotech
IOBT
$8.1M 0.6%
5,747,067
+2,469,135
+75% +$4.34M
RLYB icon
31
Rallybio
RLYB
$85.8M
$7.37M 0.54%
273,500
– –
ABCL icon
32
AbCellera Biologics
ABCL
$2.12B
$5.18M 0.38%
1,126,915
– –
SILK
33
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$5M 0.37%
333,884
– –
TMCI icon
34
Treace Medical Concepts
TMCI
$309M
$4.72M 0.35%
360,000
– –
LVTX
35
DELISTED
LAVA Therapeutics
LVTX
$3.53M 0.26%
2,400,000
– –
MQ icon
36
Marqeta
MQ
$1.66B
$2.64M 0.2%
110,390
– –
CYT
37
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$1.92M 0.14%
676,379
-2,986,257
-82% -$8.23M
DMRA
38
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$1.8M 0.13%
99,912
– –
KNTE
39
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$1.14M 0.08%
815,707
– –
SPRO icon
40
Spero Therapeutics
SPRO
$73M
$567K 0.04%
468,902
– –
VERV
41
DELISTED
Verve Therapeutics
VERV
– –
-500,000
Closed -$9.38M
GRTX
42
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
– –
-2,100,000
Closed -$6.55M
1
2

Similar funds

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
SPC
Stony Point Capital New York $1.24B AUM 32.69% 1-Year Est. Return
SC
Strategy Capital Los Altos, California $1.22B AUM 27.02% 1-Year Est. Return

Novo Holdings A/S's Q3 2023 Portfolio in Review

As of Q3 2023, Novo Holdings A/S held 42 positions worth $1.35B, up 4.6% from $1.29B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Novo Holdings A/S deployed $135M of net new capital in Q3 2023, opening 1 new position and adding to 8 existing holdings. Its largest new stake was Brookfield Asset Management: 627,207 shares worth $20.9M.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 53% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Cyteir Therapeutics, Inc. Common Stock, an estimated $8.23M trimmed.

  • Novo Holdings A/S's largest Q3 2023 buy was Brookfield Asset Management: 627,207 shares worth $20.9M.
  • Novo Holdings A/S added most to Brookfield in Q3 2023, an estimated $110M increase.
  • Novo Holdings A/S's biggest Q3 2023 reduction was Cyteir Therapeutics, Inc. Common Stock, cutting an estimated $8.23M.
  • Novo Holdings A/S fully exited Verve Therapeutics in Q3 2023, selling an estimated $9.38M.
  • Novo Holdings A/S's ten largest holdings make up 58% of its $1.35B portfolio in Q3 2023.
  • Novo Holdings A/S opened 1 new position and closed 2 in Q3 2023.
  • Novo Holdings A/S's portfolio value rose 4.6% quarter-over-quarter to $1.35B.

Based on Novo Holdings A/S's 13F filing for Q3 2023, filed 14 Nov 2023.